NASDAQ:DMAA · NASDAQ Global Select
+$0.00 today
Vol 0.00M · Avg 0.11M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Company filings are the primary source for understanding what changed inside Drugs Made In America Acquisition Corp. Ordinary Shares before the market fully reacts. Review recent DMAA disclosures alongside price history and peer context to identify new risks, accounting changes, strategic updates, capital allocation decisions, and operating details that may affect the intrinsic value case.
Price History
Dividend-adjusted closing price
Change
+4.50%
Period High
$10.68
Period Low
$10.22
Latest
$10.68
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
Berto Acquisition Corp.
NASDAQ:TACO
$394.70M
Centurion Acquisition Corp.
NASDAQ:ALF
$391.36M
Berto Acquisition Corp. Unit
NASDAQ:TACOU
$378.32M
Titan Acquisition Corp.
NASDAQ:TACH
$360.18M
Oyster Enterprises II Acquisition Corp
NASDAQ:OYSE
$348.64M
SIM Acquisition Corp. I
NASDAQ:SIMA
$333.35M
Live Oak Acquisition Corp. V Class A Ordinary Shares
NASDAQ:LOKV
$331.20M
Renatus Tactical Acquisition Corp I Class A Ordinary Shares
NASDAQ:RTAC
$328.13M
Mountain Lake Acquisition Corp. Class A
NASDAQ:MLAC
$30.37M
What is the latest DMAA filing?
The latest filing shown is SC 13G dated Jun 26, 2026.
How many recent filings does DMAA have?
Intrinsic Alpha currently shows 20 recent filings for DMAA.
Explore More
Continue the stock analysis
Jump to another research area for this company.